Evaluation and Management of Mild Hematuria

Initial Confirmation and Exclusion of Benign Causes

The American Academy of Family Physicians recommends confirming true hematuria by microscopic urinalysis showing ≥3 RBCs/HPF, rather than relying solely on dipstick, which has limited specificity (65-99%) and can yield false positives from myoglobinuria, hemoglobinuria, or menstrual contamination 4, 2
The American Urological Association suggests excluding transient benign causes, including menstruation, vigorous exercise, sexual activity, viral illness, trauma, and urinary tract infection, before proceeding with extensive workup 4, 2
If a urinary tract infection is suspected, the American College of Physicians recommends obtaining urine culture before starting antibiotics, treating appropriately, then repeating urinalysis 6 weeks after treatment completion to confirm resolution of hematuria 2, 3

The American Urological Association stratifies patients into three risk categories that determine evaluation intensity, with high-risk patients requiring full evaluation 1, 2
The American Urological Association defines low-risk patients as women age <60 years or men age <40 years, never smokers or <10 pack-years smoking history, and 3-10 RBCs/HPF on single urinalysis 3, 4
The American Urological Association defines high-risk patients as those with age ≥60 years, >30 pack-years smoking history, >25 RBCs/HPF on single urinalysis, or history of gross hematuria, occupational exposure to chemicals/dyes, history of urologic disorders, irritative voiding symptoms, or recurrent UTIs despite appropriate antibiotics 3, 4

The American Society of Nephrology recommends assessing for indicators of glomerular disease, such as dysmorphic RBCs >80% on urinary sediment examination, red blood cell casts, significant proteinuria >500 mg/24 hours, or elevated serum creatinine, before proceeding with urologic evaluation 4, 2
The American Society of Nephrology suggests referring patients to nephrology if proteinuria >1,000 mg/24 hours, or if there are signs of glomerular disease, such as dysmorphic RBCs >80% with red cell casts, elevated creatinine, or associated hypertension 4, 2

The American Urological Association recommends that all high-risk patients require cystoscopy and upper tract imaging, with multiphasic CT urography as the preferred imaging modality 1, 2
The American Urological Association suggests that cystoscopy is mandatory for all patients ≥40 years with microscopic hematuria to detect bladder tumors and carcinoma in situ 2, 5
The American Urological Association recommends urine cytology in high-risk patients to detect urothelial cancers 5

The American Urological Association recommends repeat urinalysis at 6, 12, 24, and 36 months with blood pressure monitoring at each visit for patients with persistent hematuria and negative workup 2, 5
The American Urological Association suggests considering comprehensive re-evaluation in 3-5 years if hematuria persists or recurs, particularly in high-risk populations 1, 2

The American Urological Association recommends never attributing hematuria solely to anticoagulation or antiplatelet therapy, as these medications may unmask underlying pathology but do not cause hematuria themselves 2, 3
The American Urological Association suggests not delaying evaluation in patients with rapid recurrence of UTI with the same organism, as this may indicate calculus disease 2
The American Urological Association recommends maintaining equal vigilance across sexes, as women are significantly underreferred for hematuria evaluation despite similar cancer risk 3